| Cell line name |
OV-MZ-32 |
|---|
| Synonyms |
OVMZ32 |
|---|
| Accession |
CVCL_X956 |
|---|
| Resource Identification Initiative |
To cite this cell line use: OV-MZ-32 (RRID:CVCL_X956) |
|---|
| Disease |
Ovarian carcinoma (NCIt: C4908) |
|---|
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
|---|
| Sex of cell |
Female |
|---|
| Age at sampling |
Age unspecified |
|---|
| Category |
Cancer cell line |
|---|
| Publications | PubMed=10741907; DOI=10.1007/s004320050023
Qi Wu, Rolf Kreienberg, Ingo Bernard Runnebaum;
Growth suppression of human ovarian carcinoma OV-MZ-2a and OV-MZ-32 cells mediated by gene transfer of wild-type p53 enhanced by chemotherapy in vitro.
J. Cancer Res. Clin. Oncol. 126:139-144(2000) PubMed=11242531; DOI=10.1089/10430340150504019
Ansgar Bruning, Tanja Kohler, Sven Roy Quist, Shan Wang-Gohrke, Volker J. Mobus, Rolf Kreienberg, Ingo Bernard Runnebaum;
Adenoviral transduction efficiency of ovarian cancer cells can be limited by loss of integrin beta3 subunit expression and increased by reconstitution of integrin alphaVbeta3.
Hum. Gene Ther. 12:391-399(2001) PubMed=15153938; DOI=10.1038/sj.cgt.7700727
Sven Roy Quist, Shan Wang-Gohrke, Tanja Kohler, Rolf Kreienberg, Ingo Bernard Runnebaum;
Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status.
Cancer Gene Ther. 11:547-554(2004) |
|---|
| Cross-references |
|---|
| Encyclopedic resources |
Wikidata; Q54936859
|
|---|
| Entry history |
|---|
| Entry creation | 05-Sep-2014 |
|---|
| Last entry update | 21-Mar-2023 |
|---|
| Version number | 4 |
|---|
